Baby Changing in Health Centers Act
Summary
HR6370 (Baby Changing in Health Centers Act) is an early-stage, narrow procurement bill requiring baby changing tables in federally funded health centers. It authorizes no direct appropriations, has only one cosponsor, and is stuck at committee referral. Real market data shows $KMB trading at $96.82 within its 52-week range with no abnormal volume; this bill has zero material revenue impact on any publicly traded company.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR6370 is a procedural bill with no funding and no legislative momentum.
- 2.The total addressable market for baby changing tables under this bill is an estimated $1M-$3.5M — immaterial to any publicly traded company.
- 3.$KMB and $PG show no market reaction to this bill; both trade normally within 52-week ranges.
Market Implications
No market implications. $KMB closed at $96.82 on April 30, 2026, within its 52-week range. There is zero causal link between this bill and any stock movement. Investors should ignore HR6370 entirely for portfolio decisions.
Full Analysis
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Expanding Child Care Access Act of 2025
To prohibit a person from making a misleading recycled content claim in advertising, marketing, selling, or offering for sale a product to a consumer, and for other purposes.
Growing and Preserving Innovation in America Act of 2025
No Tax Breaks for Outsourcing Act
To amend the Federal Trade Commission Act to include requirements for recyclable, compostable, and reusable claims for packaging for a consumer product, and for other purposes.
Homeopathic Drug Product Safety, Quality, and Transparency Act
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.